Compound 1205
Identifiers
- Canonical SMILES:
FC(F)(F)c1cc(ccc1Sc1ccccc1N1CCCCC1)[C@@H]1C[C@H]1C(=O)NCCCN1CCCC1=O
- IUPAC name:
N-[3-(2-oxopyrrolidin-1-yl)propyl]-2-[4-(2-piperidin-1-ylphenyl)sulfanyl-3-(trifluoromethyl)phenyl]cyclopropane-1-carboxamide
- InChi:
InChI=1S/C29H34F3N3O2S/c30-29(31,32)23-18-20(21-19-22(21)28(37)33-13-7-17-35-16-6-10-27(35)36)11-12-25(23)38-26-9-3-2-8-24(26)34-14-4-1-5-15-34/h2-3,8-9,11-12,18,21-22H,1,4-7,10,13-17,19H2,(H,33,37)/t21-,22+/m0/s1
- InChiKey:
TUIWCAJBTHNBBI-FCHUYYIVSA-N
External links
![]() 168317870 |
![]() 19174439 |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
0 | 1 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
LFA / ICAM | 7.40 | immune system disease | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 545.23 g/mol | |||
HBA | 5 | |||
HBD | 1 | |||
HBA + HBD | 6 | |||
AlogP | 4.95 | |||
TPSA | 52.65 | |||
RB | 10 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 0 | 1 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5638 | Butaperazine | DB13213 | |
0.5594 | Periciazine | DB01608 | |
0.5422 | Propiopromazine | DB11540 | |
0.5360 | Carphenazine | DB01038 | |
0.5349 | Mequitazine | DB01071 | |
0.5224 | Etymemazine | DB11517 | |
0.5185 | Triflupromazine | DB00508 | |
0.5141 | Trifluoperazine | DB00831 | |
0.5137 | Fluphenazine | DB00623 | |
0.5135 | Metopimazine | DB13591 | |
0.5106 | Acepromazine | DB01614 | |
0.5066 | Acetophenazine | DB01063 | |
0.5000 | Propiomazine | DB00777 | |
0.4929 | Thioridazine | DB00679 | |
0.4923 | Methdilazine | DB00902 |